| ID | 10029 |
| Vaccine Name | Spikevax |
| Disease Name | COVID-19 |
| Disease Classification | Respiratory |
| Virus Name | SARS-CoV-2 virus |
| Nucleic Acid Content | positive-sense, single-stranded RNA |
| Vaccine Type | RNA based vaccine |
| Vaccine Status | Approved |
| Manufacturer | Moderna Inc. |
| Year of Manufacturing | NA |
| Manufacturing Country | NA |
| Age | NA |
| Dosage | 2 doses 4 weeks apart |
| Administration Route | Intramuscular |
| Adjuvant | NA |
| Target Strain | NA |
| Description | NA |
| Approving Organisation | US FDA |
| Collaborating Organisation | NA |
| Other Countries | USA, Canada, Israel, European Union |
| Trade Name | mRNA-1273, CX-024414, COVID-19 mRNA Vaccine Moderna, TAK-919, Moderna COVID‑19 Vaccine, COVID‑19 Vaccine Moderna, COVID-19 Vaccine Moderna Intramuscular Injection, Elasomeran |
| PMID | 33826439 |
| Clinical Trial ID | NA |
| Reference Link | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040490/ |
| Additional Links | NA
|